1. Home
  2. CLPS vs EVAX Comparison

CLPS vs EVAX Comparison

Compare CLPS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

N/A

Current Price

$1.06

Market Cap

31.6M

Sector

Technology

ML Signal

N/A

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.17

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
EVAX
Founded
2005
2008
Country
Hong Kong
Denmark
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.6M
25.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CLPS
EVAX
Price
$1.06
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
18.0K
211.1K
Earning Date
03-06-2026
05-07-2026
Dividend Yield
14.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$2.72
52 Week High
$1.88
$12.15

Technical Indicators

Market Signals
Indicator
CLPS
EVAX
Relative Strength Index (RSI) 63.60 56.30
Support Level $0.84 $2.91
Resistance Level $1.12 $3.62
Average True Range (ATR) 0.05 0.25
MACD 0.00 0.00
Stochastic Oscillator 84.24 51.85

Price Performance

Historical Comparison
CLPS
EVAX

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: